Quantcast

Latest Friedreich's ataxia Stories

2008-11-06 09:00:45

WALTHAM, Mass., Nov. 6 /PRNewswire-FirstCall/ -- Repligen Corporation today reported results for the second quarter of fiscal year 2009, ended September 30, 2008. Total revenue for the quarter was $5,090,000 compared to total revenue of $5,352,000 for the second quarter of fiscal year 2008 ended September 30, 2007. Total revenue was comprised of product revenue and royalty and research revenue. Product revenue, comprised of Protein A revenue, for the second quarter of fiscal year 2009...

2008-10-10 09:00:18

LIESTAL, SWITZERLAND--(Marketwire - Oct. 10, 2008) - Santhera Pharmaceuticals (SWX:SANN), a Swiss specialty pharmaceutical company with a focus on neuromuscular diseases, announced today the launch of CATENA(R) (idebenone) in Canada. The drug is indicated for the treatment of Friedreich's Ataxia, a rare neuromuscular disease that results in the degeneration of nerve and muscle tissue. Catena is the first and only approved therapy in Canada to treat this devastating genetic disorder. Santhera...

2008-09-16 12:00:10

WALTHAM, Mass., Sept. 16 /PRNewswire-FirstCall/ -- Repligen Corporation today reported publication of a preclinical study demonstrating that a novel histone deacetylase (HDAC) inhibitor improved disease symptoms in a transgenic animal model of Huntington's disease. The study, led by scientists at The Scripps Research Institute, demonstrated that oral administration of the drug candidate to the mice after the onset of symptoms slowed the progression of disease. Treated animals showed...

2008-08-07 09:01:05

WALTHAM, Mass., Aug. 7 /PRNewswire-FirstCall/ -- Repligen Corporation today reported results for the first quarter of fiscal year 2009, ended June 30, 2008. Total revenue for the quarter was $13,660,000 compared to total revenue of $5,979,000 for the first quarter of fiscal year 2008 ended June 30, 2007, an increase of $7,681,000 or 128%. Total revenue was comprised of product revenue and royalty and other revenue. Product revenue for the first quarter of fiscal year 2009 was $5,693,000...

2008-07-24 12:01:22

Santhera Pharmaceuticals has announced that Health Canada has approved SNT-MC17/idebenone, subject to certain conditions, for the treatment of Friedreich's Ataxia. Health Canada's decision is said to be the first marketing authorization worldwide for any Friedreich's Ataxia therapy. The new drug will be marketed in Canada under the brand name Catena. Launch of Catena is anticipated by the end of October 2008. In clinical studies submitted to Health Canada as part of the approval process,...

2008-07-24 03:00:18

Santhera Pharmaceuticals (SWX: SANN), a Swiss specialty pharmaceutical company focused on neuromuscular diseases, announced today that Health Canada has approved with conditions SNT-MC17/idebenone for the treatment of Friedreich's Ataxia. Health Canada's decision is the first marketing authorization worldwide for any Friedreich's Ataxia therapy. The new drug will be marketed in Canada under the brand name Catena(R). Santhera has established a wholly owned Canadian subsidiary,...

2008-06-18 21:00:23

MitoSciences has today released two new products for measuring Mitochondrial Biogenesis, a crucial biological process that is receiving increased attention due to its link to increased life span and greater resistance to disease. Mitochondrial Biogenesis is at the center of highly-publicized recent studies describing the positive effects of resveratrol (the healthful component in red wine and an activator of proteins called sirtuins) and the creation of the so-called Super Mouse....


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related